Key result
A 59-year-old man with oral cancer developed a pulmonary thromboembolism during preoperative TPF chemotherapy but successfully completed the treatment after prompt anticoagulant therapy.
Why the study?
Chemotherapy is a moderate risk factor for thromboembolism, but reports regarding its development during chemotherapy for oral cancer are scarce.
Case Report (n=1)
No
Prompt administration of anticoagulants and beta-blockers can successfully manage pulmonary thromboembolism occurring as a complication of chemotherapy for oral cancer, allowing for the continuation of cancer treatment.
Clinicians should monitor for early PTE during TPF chemotherapy in oral cancer; leaves open whether thromboprophylaxis trials are warranted.
In addition to cancer-bearing status, chemotherapy is one of the moderate risk factors for the development of thromboembolism. However, there are few reports about it for oral cancer. Here, we report a case of pulmonary thromboembolism (PTE) that developed during chemotherapy for oral cancer. The patient was a 59-year-old man with left maxillary gingival cancer (T2N2bM0, Stage ⅣA). He complained of chest pain and dyspnea on the third day of the first course of TPF (docetaxel, cisplatin, 5-FU), which was performed as preoperative chemotherapy. Therefore, we performed an electrocardiogram and contrast-enhanced CT imaging. ST elevation, tachycardia and atrial fibrillation were observed on the electrocardiogram. PTE was also observed in his left lung in CT images. We immediately started the administration of β -blocker and anticoagulant therapies. After that the patient’s subjective symptoms disappeared and the electrocardiogram showed stability two days later. Therefore, chemotherapy was continued and completed. After three weeks, a left maxillary partial resection and left radical neck dissection were performed. Following the operation, there have been no PTE symptoms and he is making good progress.
No takes yet. Share an insight, caveat, or question.
Shibata et al. (2022) conducted a case report in Oral cancer (left maxillary gingival cancer) and pulmonary thromboembolism (n=1). TPF chemotherapy (docetaxel, cisplatin, 5-FU) was evaluated on Development and management of pulmonary thromboembolism. A 59-year-old man with oral cancer developed a pulmonary thromboembolism during preoperative TPF chemotherapy but successfully completed the treatment after prompt anticoagulant therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: